http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107286169-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
filingDate | 2016-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2020-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2020-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-107286169-B |
titleOfInvention | Tankyrase Inhibitor |
abstract | The invention belongs to the technical field of medicine, and specifically relates to tankyrase inhibitors represented by general formula (I), pharmaceutically acceptable salts, esters, solvates or stereoisomers thereof, wherein R 1 , R 2 , R3 , R4 , R5 , m, n, p, Z, L, X and Y are as defined in the specification. The present invention also relates to the preparation method of these compounds, the pharmaceutical preparations and pharmaceutical compositions containing these compounds, and the preparation of the compounds, their pharmaceutically acceptable salts, esters, solvates or their stereoisomers for treatment and/or prevention Drug application in cancer and related diseases mediated by tankyrase. |
priorityDate | 2016-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 283.